Some providers featured on this site may compensate us. This may affect the order and placement of listings but does not influence our editorial ratings or reviews.
GLP-1 Pills vs Injections: Which Is Better for Weight Loss?
The pills have arrived: two oral GLP-1s are now FDA-approved for weight loss. Here’s an honest, side-by-side comparison of results, cost, convenience, and how to choose between a daily tablet and a weekly injection.
Last updated: Sep 1, 2026
The short answer
Tirzepatide injection still wins on peak average weight loss (up to ~22.5% in trials), but the newest pills now rival semaglutide injections - oral Wegovy hit ~16.6% in its trial. Pills win on convenience: a daily tablet, no needles. Pick tirzepatide for maximum average results; pick an oral GLP-1 if avoiding needles matters more to you.
Our top 2 picks
Our two recommended GLP-1 providers, shown with the same verified pricing and ratings as our full comparison.
embody offers doctor-prescribed GLP-1 weight loss treatment - compounded semaglutide and tirzepatide injections - through a 100% online process. Getting started takes a roughly 5-minute health qualifier, after which a medical practitioner reviews your chart (embody says usually within 24 hours, often under 5). Pricing is flat and simple: $69/month for semaglutide and $119/month for tirzepatide, with no insurance required, no hidden fees, and no clinic visits. Medication ships in 1-2 days in temperature-controlled, tracked, insured packaging, and embody is LegitScript-certified and works with US-based 503A compounding pharmacies. On Trustpilot, embody averages 3.8 across 8,398 reviews - an honest, mixed-to-positive record whose recent reviews cluster around two themes: responsive, proactive customer service ('from my very first inquiry I've had excellent communication... customer service updated me every step,' writes one tirzepatide patient) and the no-surprises pricing ('Love the fact that there are no surprises as in costly up front cost'). A 3.7 also means a minority of customers had negative experiences - worth reading both ends of the reviews before deciding, as with any provider.
altRx bills itself as "the #1 most affordable GLP-1 program," and its published prices largely back that up: compounded GLP-1 (semaglutide) from $89/month and GLP-1 + GIP (tirzepatide) from $149/month - flat at every dose, so the price doesn't climb as you titrate up - alongside one of the few genuine brand-name shelves in this space (Ozempic $1,149, Zepbound $1,249, Wegovy $1,579 per month). It's a self-pay telehealth service: you complete a short assessment, a licensed provider (physician, PA, or nurse practitioner) reviews it, and if appropriate a prescription goes to a licensed US pharmacy, with free shipping in about 5-7 days. No insurance is required, Buy Now, Pay Later is available, and you can pause or cancel anytime. Two things to know before the details: shipping is slower than the 1-2 day providers (embody, DirectMeds), and Trustpilot does not currently display an aggregate score on altRx's profile - the individual reviews we quote on this page are real, but there's no independent average to lean on the way there is for rivals like Medvi (4.3 across 14,836) or embody (3.8 across 8,398). One of the real 4-star reviews we surface notes a refill 'yet to be fulfilled with zero reason as to why' - worth factoring in alongside the price advantage.
Daily pill; oral semaglutide needs empty-stomach timing, orforglipron has no food/water restrictions
One injection a week; no daily routine
FDA status
Two oral GLP-1s now approved for weight management
Established, long-approved
Cost (telehealth)
Brand pills new to market - pricing varies; confirm current cash/insurance
Compounded options often from ~$69-$149/mo
Best for
People who want to avoid needles or a no-timing daily pill
People prioritizing the greatest average weight loss
The pills: oral GLP-1s
Oral GLP-1s deliver the same class of medication as the injections, in tablet form - and the landscape changed fast. Oral Wegovy(oral semaglutide 25mg) was FDA-approved in December 2025 as the first oral GLP-1 for chronic weight management, with about 16.6% mean weight loss in the OASIS-4 trial when taken as directed - roughly matching injectable Wegovy. It’s a once-daily tablet, but as a peptide it must be taken on an empty stomach with a small sip of water, waiting about 30 minutes before eating, drinking, or other medications.
Orforglipron(brand name Foundayo, from Eli Lilly) followed with FDA approval in April 2026. As a small-molecule (non-peptide) GLP-1, it’s the first weight-loss pill that can be taken any time of day with no food or water restrictions - a real convenience edge. It reached up to about 12.4% weight loss at 72 weeks in the ATTAIN-1 trial. Separately, Rybelsus (lower-dose oral semaglutide) remains FDA-approved for type 2 diabetes rather than weight loss, at doses that produce less weight loss than the newer 25mg pill. See our full weight loss pills guide for the complete oral landscape.
The injections: semaglutide & tirzepatide
The injectables set the benchmark. Semaglutide (Wegovy) produces ~15% average weight loss in trials, and tirzepatide (Zepbound) reaches up to ~22.5% - still the strongest average performer of any GLP-1, pill or shot. Both are once-weekly injections, and through telehealth, compounded versions are often the most affordable path to GLP-1 treatment.
Which should you choose?
Lean toward pills if…
You want to avoid needles entirely
A simple daily tablet fits your routine better
You’re starting out and want a lower-commitment option
Lean toward injections if…
Maximum average weight loss is your priority
You prefer a once-weekly routine over a daily one
You want the most established, well-studied results
Either way, a licensed clinician determines the right medication, dose, and titration for your health profile.
Get started online
Compare licensed telehealth providers on pricing, medical support, and value - whether you lean toward a pill or an injection.
It now depends on which pill. Oral Wegovy (oral semaglutide 25mg) produced about 16.6% mean weight loss in the OASIS-4 trial when taken as directed - roughly matching injectable Wegovy. Orforglipron (Foundayo) reached up to about 12.4% in ATTAIN-1. Injectable tirzepatide (Zepbound) still leads on peak average results, up to ~22.5% in trials. So the newest pills rival semaglutide injections, while tirzepatide injection remains the strongest average performer.
Which is cheaper, GLP-1 pills or injections?
It depends on the specific medication and provider. Through telehealth, compounded injectable GLP-1s are often the most affordable route (frequently around $69-$149/month, including consultations). The new brand-name oral pills are just reaching the market, so pricing varies - confirm current cash, insurance, and telehealth pricing before deciding. The best value comes down to which medication you're prescribed and the plan you choose.
Do GLP-1 pills have fewer side effects than injections?
The side-effect profile is broadly similar because they're the same drug class - most commonly nausea and other GI effects, especially early on. The route (pill vs injection) doesn't dramatically change this; dose and how gradually you titrate matter more.
Can you switch from injections to pills, or vice versa?
Often yes, under medical supervision. Many people move between formulations based on tolerance, convenience, or availability. A licensed clinician determines the right medication, dose, and titration when switching - there's no DIY dose conversion between them.
Is there a GLP-1 pill approved specifically for weight loss?
Yes - two, as of 2026. The FDA approved oral Wegovy (oral semaglutide 25mg) in December 2025, the first oral GLP-1 for chronic weight management, and orforglipron (Foundayo) from Eli Lilly in April 2026, the first that can be taken any time of day with no food or water restrictions. Rybelsus (lower-dose oral semaglutide) remains approved for type 2 diabetes rather than weight loss.
More GLP-1 guides
The rest of our weight-loss medication guides, kept to the same verified-price standard.
Sources: FDA approvals and prescribing information - oral Wegovy (oral semaglutide 25mg) approved December 2025 and orforglipron (Foundayo) approved April 2026; published clinical trial data (STEP and OASIS for semaglutide, SURMOUNT for injectable tirzepatide, ATTAIN for orforglipron). Weight loss figures are trial averages; individual results vary. Brand names are trademarks of their respective manufacturers.
treatmentshub.com is not a medical provider and does not prescribe medications. This page is for educational and comparison purposes only and is not medical advice. GLP-1 medications require evaluation and supervision by a licensed healthcare provider.
